Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain

• Published in: Expert review of pharmacoeconomics & outcomes research Vol. 13; no. 3; pp. 381 - 391
• Main Authors: Alba, Emilio, Ciruelos, Eva, López, Rafael, López-Vega, José Manuel, Lluch, Ana, Martín, Miguel, Muñoz, Montserrat, Sánchez-Rovira, Pedro, Seguí, Miguel Ángel, Liria, Marta Rubio, Pérez-Alcántara, Ferran
• Format: Journal Article
• Language: English
• Published: England Informa Healthcare 01.06.2013; Taylor & Francis; Expert Reviews Ltd
• Subjects: Albumin-Bound Paclitaxel; Albumins - administration & dosage; Albumins - economics; Albumins - therapeutic use; Antineoplastic Agents, Phytogenic - administration & dosage; Antineoplastic Agents, Phytogenic - economics; Antineoplastic Agents, Phytogenic - therapeutic use; Approximation; breast; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - economics; Breast Neoplasms - pathology; cancer; Cancer therapies; Castor Oil - analogs & derivatives; Castor Oil - chemistry; Chemotherapy; Clinical trials; cost; Cost analysis; Cost benefit analysis; Cost Savings; COSTABRAX; Costs; Disease; Drug Administration Schedule; Drug therapy; Economic aspects; Female; Humans; Markov Chains; Metastasis; Models, Economic; Mortality; nab-paclitaxel; Nanoparticles; Neoplasm Metastasis; Ovarian cancer; Paclitaxel; Paclitaxel - administration & dosage; Paclitaxel - economics; Paclitaxel - therapeutic use; Patients; Pharmacoeconomics; Quality of life; Quality-Adjusted Life Years; Sensitivity analysis; Spain; Time Factors; Toxicity; Treatment Outcome; Womens health; Working groups; Spain
• ISSN: 1473-7167; 1744-8379
• DOI: 10.1586/erp.13.18

Aim: The COSTABRAX study evaluated the cost-effectiveness of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) versus polyethylated castor oil-based standard paclitaxel (sb-paclitaxel) in the treatment of patients with previously treated metastatic breast cancer in Spain. Materials & methods: Efficacy data were obtained from the CA012 trial (nab-paclitaxel administered every 3 weeks [q3w] and sb-paclitaxel q3w) and indirect comparison (sb-paclitaxel administered weekly), and were modeled to a time horizon of 5 years using a Markov model. The analysis was performed from the National Health Service perspective. Use of resources and key assumptions of the model were validated by a panel of 22 local oncologists. Results: Compared with sb-paclitaxel q3w, nab-paclitaxel q3w was cost effective, with a cost per life year gained of €11,088 and a cost per quality-adjusted life year of €17,808. Compared with sb-paclitaxel administered weekly, it showed savings of €711 per patient. Conclusion: The COSTABRAX study showed that nab-paclitaxel q3w is a cost-effective alternative compared with sb-paclitaxel q3w and a cost-saving alternative to sb-paclitaxel administered weekly in Spain.